Here are the 10-K annual reports from Rhythm Pharmaceuticals, Inc. (RYTM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RYTM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RYTM filings page.
Rhythm Pharmaceuticals files its Annual Report outlining progress in rare obesity therapies. The company is a commercial-stage biopharma focused on melanocortin-4 receptor (MC4R) agonists, led by IMCIVREE (setmelanotide), and has generated approximately $422.5 million from product sales to date while remaining unprofitable.
IMCIVREE is already approved in the United States, European Union, United Kingdom and other regions for several rare MC4R pathway obesities, including Bardet-Biedl syndrome and biallelic POMC, PCSK1 and LEPR deficiencies, with use now extending to children as young as 2 years in key markets. A Phase 3 trial in acquired hypothalamic obesity showed a placebo‑adjusted body mass index reduction of 19.8%, supporting regulatory reviews in the United States and Europe, including an FDA PDUFA goal date of March 20, 2026.
Rhythm also highlights a broad pipeline: the Phase 3 EMANATE trial in multiple genetically defined MC4R pathway diseases with topline data expected in March 2026, positive exploratory data in Prader‑Willi syndrome, and two next‑generation MC4R agonists—oral bivamelagon, which produced up to a 9.3% BMI reduction in a Phase 2 hypothalamic obesity trial, and weekly injectable RM‑718. The company is investing in large-scale genetic testing and early research in congenital hyperinsulinism while warning that it will need additional funding and continues to face significant clinical, regulatory and commercial risks.